Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2306 - A Phase II Study of Nedaplatin and nab-Paclitaxel for Patients with Previously Untreated Advanced Squamous Cell Lung Cancer (KRSG1302)

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Tomohide Sugiyama

Citation

Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292

Authors

T. Sugiyama1, T. Kasai1, N. Koyama2, K. Kobayashi3, E. Hoshi4, M. Nakayama5, K. Mori6

Author affiliations

  • 1 Department Of Medical Oncology, Tochigi Cancer Center, 320-0834 - Utsunomiya/JP
  • 2 Department Of Clinical Oncology, Tokyo Medical University Hachioji Medical Center, 193-0944 - Tokyo/JP
  • 3 Respiratory Medicine, Saitama Medical University Internatl Medical Centre, 350-1298 - Saitama/JP
  • 4 Thorcic Surgery, Saitama Cardiovascular and Respiratory Center, 360-0197 - Kumagaya/JP
  • 5 Thorcic Surgery, Saitama Medical Center, 350-8550 - Kawagoe/JP
  • 6 Respiratory Medicine, Tsuboi cancer center Hospital, 963-0197 - Koriyama/JP
More

Resources

Abstract 2306

Background

Nedaplatin (N) and nab-paclitaxel (nab-P) are efficacious in the treatment of non-small cell lung cancer (NSCLC), especially squamous cell lung cancer. Although a combination of N and nab-P was expected in the treatment of squamous cell lung cancer, there was no sufficient data.

Methods

The eligibility criteria were no prior chemotherapy; stage IIIB or stage IV squamous cell lung cancer; a performance status (PS) of 0–1; 75 > age > 20 years; and adequate hematologic, hepatic, and renal function. Patients (pts) received escalating doses of nab-P under a fixed dose of N (100 mg/m2, day 1) every 3 weeks in the phase I part. The initial dose of nab-P was 100 mg/m2 of day 1, 8 (level 1), and that of the next dose was 100 mg/m2 of day 1, 8, 15 (level 2). In the phase II part, pts received the recommended dose (RD) of N/nab-P. The primary endpoint was tumor response, which was measured using Response Evaluation Criteria in Solid Tumors 1.1.

Results

Five pts were enrolled in the phase I part. Three pts of level 1 have experienced no dose-limiting toxicities (DLTs). Two pts of level 2 have experienced DLTs, which were febrile neutropenia and the down of PS, respectively. Therefore, level 1 was determined to RD. 23 pts were enrolled in phase II part. Three pts in level 1 and 23 pts in phase II were evaluable, together. Partial response, stable disease, and progressive disease were noted in 21, 0, and 2 pts, respectively, yielding a response rate of 91.3% (95%confidence interval [CI]: 72.0–98.9). The median progression-free survival was 223 days (95%CI: 144–330), and the median survival time was 358 days (95%CI: 255–950). The grade 3 and 4 toxicities observed during all cycles were neutropenia (5 and 9 pts), anemia (6 and 2 pts), thrombocytopenia (5 and 3 pts). Grade 3 febrile neutropenia, pneumonia, and acute coronary syndrome were observed in 1, 2, and 1 pts, respectively. However, there was no treatment related death.

Conclusions

A combination of N (100 mg/m2, day 1) and nab-P (100 mg/m2, day 1, 8) every 3 weeks was the recommended dose. N/nab-P in this recommended dose appears to be efficacious and torerable in patients with untreated advanced squamous cell lung cancer.

Clinical trial identification

Legal entity responsible for the study

Kanto Respiratory Disease Study Group (KRSG)/JAPAN.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.